Insmed to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Thursday, February 25, 2021

Rhea-AI Summary

Insmed Incorporated (Nasdaq: INSM) will release its fourth-quarter and full-year 2020 financial results on February 25, 2021. Management will host a conference call at 8:30 a.m. ET to discuss these results and provide a business update. Interested participants can join by dialing the provided numbers or via a live webcast. The replay of the call will be available two hours post completion until March 27, 2021. Insmed focuses on therapies for serious rare diseases, with its first product approved for a chronic lung disease.

Positive

• Insmed will release its fourth-quarter and full-year 2020 financial results, indicating ongoing transparency with shareholders.
• Management will provide a business update during the conference call, suggesting potential positive developments.

Negative

• None.

BRIDGEWATER, N.J., Feb. 12, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its fourth quarter and full year 2020 financial results on Thursday, February 25, 2021.

Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Thursday, February 25, 2021 to discuss the financial results and provide a business update.

Shareholders and other interested parties may participate in the conference call by dialing (833) 340-0284 (domestic) or (236) 712-2425 (international) and referencing conference ID number 4261618. The call will also be webcast live on the company's website at www.insmed.com.

A replay of the conference call will be accessible approximately two hours after its completion through March 27, 2021 by dialing (800) 585-8367 (domestic) or (416) 621-4642 (international) and referencing conference ID number 4261618. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company's website at www.insmed.com.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States and the European Union to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a growing footprint across Europe and in Japan. For more information, visit www.insmed.com.

Contact: 

Investors:

Eleanor Barisser
Associate Director, Investor Relations
Insmed
eleanor.barisser@insmed.com 

Media:

Mandy Fahey
Senior Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/insmed-to-host-fourth-quarter-and-full-year-2020-financial-results-conference-call-on-thursday-february-25-2021-301221945.html

SOURCE Insmed Incorporated

FAQ

When will Insmed announce its fourth-quarter and full-year 2020 financial results?

Insmed will announce its financial results on February 25, 2021.

What time is the Insmed conference call scheduled for?

The conference call is scheduled for 8:30 a.m. ET on February 25, 2021.

How can I participate in the Insmed conference call?

Participants can join by dialing (833) 340-0284 domestically or (236) 712-2425 internationally and referencing conference ID 4261618.

Will there be a replay of the Insmed conference call?

Yes, a replay will be available approximately two hours after the call and will last until March 27, 2021.

What is the focus of Insmed as a company?

Insmed focuses on developing therapies for serious and rare diseases, particularly chronic lung diseases.